Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045793 · ClinicalTrials.gov registry record · Phase 2
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
A Phase 2 study, sponsored by Tonix Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06045793 is a Phase 2 study that was terminated before completion, run by Tonix Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT06045793, a Phase 2 study, was terminated before completion, sponsored by Tonix Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.
Interventions
- DRUG TNX-1300 (Injection)
- DRUG Placebo (Injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2025-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06045793
The ClinicalTrials.gov registry entry for NCT06045793 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TNX-1300 (Injection) is the first listed.
NCT06045793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06045793 about?
NCT06045793 is a clinical study titled "Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)". This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.
What is the current status of trial NCT06045793?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2024-08-16. Estimated completion is 2025-04-21.
What interventions are being tested in trial NCT06045793?
The interventions under investigation include: TNX-1300 (Injection) (DRUG), Placebo (Injection) (DRUG).
Who is sponsoring clinical trial NCT06045793?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.